Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer
Milena Urbini, Giorgia Marisi, Irene Azzali, Giulia Bartolini, Elisa Chiadini, Laura Capelli, Gianluca Tedaldi, Davide Angeli, Matteo Canale, Chiara Molinari, Francesca Rebuzzi, Alessandra Virga, Andrea Prochowski Iamurri, Laura Matteucci, Francesco Giulio Sullo, Silvia Angela Debonis, Chiara Gallio, Giovanni Luca Frassineti, Giovanni Martinelli, Paola Ulivi, Alessandro Passardi
Abstract
PURPOSE: Plasma circulating tumor DNA (ctDNA) is a valuable resource for tumor characterization and for monitoring of residual disease during treatment; however, it is not yet introduced in metastatic colorectal cancer (mCRC) routine clinical practice. In this retrospective exploratory study, we evaluated the role of ctDNA in patients with mCRC treated with chemotherapy plus bevacizumab. MATERIALS AND METHODS: status on tumor tissue before the start of treatment. Plasma was collected at baseline, at first clinical evaluation, and at disease progression. ctDNA analysis was performed using Oncomine Colon cfDNA Assay on the Ion S5 XL instrument. RESULTS: = .003) were observed in patients with large decline in VAF at first evaluation. CONCLUSION: ctDNA analysis is useful for molecular characterization and tumor response monitoring in patients with mCRC. Quantitative variations of released ctDNA are associated with clinical outcomes.